Back to Tirzepatide research
tirzepatide gip agonist other 2020-09-15 ClinicalTrials

Tirzepatide Significantly Slows Stomach Emptying in Overweight and Diabetic Individuals

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

Study Design

Population
Overweight and diabetic individuals.
Outcome
Stomach emptying rate.

Abstract

The Impact of Tirzepatide on Gastric Emptying (GE) in Overweight/Obese Non-diabetic Subjects and in Overweight/Obese Subjects With Type 2 Diabetes Mellitus NCT ID: NCT04407234 Status: COMPLETED Sponsor: Eli Lilly and Company Phase: PHASE1…

tirzepatide gip agonist glp 1 agonist dose mentioned
Source: clinicaltrials:NCT04407234 · Ingested 2026-04-30 · Digest: gemini-2.5-flash